General Mills-backed meat substitute developer Beyond Meat priced its shares at the top of an expanded range, but Tyson Foods had already sold its stake.

Alexandria Real Estate Equities-backed exosome therapeutics developer Codiak BioSciences is eyeing up to $86.3m in a forthcoming IPO.

Alphabet, WuXi AppTec, Celgene, Roche and Novartis are in line to exit precision oncology therapy developer Ideaya Biosciences, which has filed to go public.

Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

The We Company, valued at $47bn as of January, confidentially filed for an IPO in December that would provide exits for SoftBank and Jin Jiang International.

Astellas, Novartis and GlaxoSmithKline are in line for exits as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

The drug developer has confidentially filed for an IPO having collected $124m in funding from investors including PureTech Health, Nan Fung and Alexandria Real Estate Equities.

SoftBank Vision Fund owns more than 7% of the enterprise messaging platform developer, which could list at a valuation near $17bn.

Uber is set to raise $7.9bn to $9bn if it floats within its range, while PayPal has agreed to invest another $500m through a private placement.

O'Reilly Media, Swisscom and Deutsche Telekom-backed content management software provider has raised nearly $220m in venture funding.